Monopar Therapeutics Inc
Research Monopar Therapeutics Inc (MNPR) on Bullrun: market cap USD 517.18M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMNPR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 517.18M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 5.31M
- Free cash flow-USD 3.25M
Valuation Snapshot
latest market cap is USD 517.18M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 13.72M | -USD 12.20M | n/a | -1.85 | USD 61.83M | USD 154.92K | USD 137.83M |
| FY2024 | USD 0 | -USD 15.59M | -USD 6.40M | n/a | -4.11 | USD 45.82M | USD 0 | USD 55.04M |
| FY2023 | USD 0 | -USD 8.40M | -USD 7.86M | n/a | -3.04 | USD 7.27M | USD 0 | USD 5.59M |
| FY2022 | USD 0 | -USD 10.52M | -USD 7.23M | n/a | -4.15 | USD 8.19M | USD 8.41K | USD 10.09M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 517.18M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 436.99M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 134.26M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 5.05M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 30.62M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 40.44M | n/a | n/a | n/a |
About Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Monopar Therapeutics Inc's market cap?
Monopar Therapeutics Inc's market capitalization is USD 517.18M.
What does Monopar Therapeutics Inc do?
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.